Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the…
Pharmaceuticals, Biotechnology and Life Sciences
ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the…
MELBOURNE, Australia and DRESDEN, Germany, March 19, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today…
– Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -NEW HAVEN, Conn., March 18, 2024…
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution…
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage…
– Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in…
– Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an…
Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers // Updated U.S. CDC guidelines…
Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track…
Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and…